期刊文献+

多虑平治疗原发性失眠有效性及安全性的系统评价 被引量:13

Effectiveness and Safety of Doxepin for Primary Insomnia:A Systematic Review
原文传递
导出
摘要 目的系统评价多虑平治疗原发性失眠的有效性及安全性。方法计算机检索Cochrane图书馆(2009年第4期)、PubMed(1966~2009.12)、EMbase(1974~2009.12)、ISI(1961~2009.12)、CBM(1978~2009.12)、CNKI(1979~2009.12)、VIP(1989~2009.12)和万方(1998~2009.12)数据库,并补充查找相关会议文献及在研文献,由2名评价者独立选择研究、评价质量、提取资料并交叉核对,而后采用RevMan 5.0软件对数据进行统计分析。结果共纳入4篇文献,共171例患者。Meta分析结果表明:与安慰剂相比,中低剂量多虑平(1~25 mg)对原发性失眠患者的总睡眠时间、睡眠后觉醒时间、睡眠期间觉醒时间、睡眠有效率等睡眠质量指标的改善作用明显,其差异有统计学意义。相反,高剂量多虑平(50 mg)对绝大多数睡眠质量指标的改善与安慰剂相比并无统计学意义。而中高剂量多虑平(25~50 mg)对原发性患者的快速眼动睡眠、二期睡眠、快速眼动睡眠潜伏时间等睡眠结构指标的改善与安慰剂相比,其差异有统计学意义。结论中低剂量多虑平(1~25 mg)可有效改善原发性失眠患者的睡眠质量,但使用中等剂量多虑平治疗原发性失眠时需关注副作用及对睡眠结构的影响;尚不推荐使用高剂量多虑平(50 mg)治疗原发性失眠。由于纳入研究质量与例数有限,上述结论尚需开展更多高质量大样本的研究加以验证。 Objective To evaluate the effectiveness and safety of doxepin in the treatment of primary insomnia.Methods We searched The Cochrane Library(Issue 4,2009),PubMed(1966 to December 2009),EMbase(1974 to De-cember 2009),ISI(1961 to December 2009),CNKI(1979 to December 2009),VIP(1989 to December 2008),CBM(1978 to December 2009),and WANFANG Data(1998 to December 2009).We also searched the correlated grey literature and conference literature for complement.Data were extracted,methodologically evaluated,and cross-checked by two review-ers independently.RevMan 5.0 was used for statistical analysis.Results One randomized controlled trial and three cross trials involving 171 patients were included.The results of meta-analyses showed that total sleep time(TST),wake time during sleep(WTDS),wake time after sleep(WTAS),and sleep effciency(SE) were improved by low and medium dosage of doxepin(1-25 mg) with statistically signi cant difference compared with placebo.On the contrary,most indicators of sleep quality had no statistically signi cant difference between high dose doxepin(50 mg) and placebo.While the sleep-ing structural indicators of rapid eye movement sleep(REM),rapid-eyemovement latency(REM-L),and sleep stage II(St.II) were changed by high and medium dosage of doxepin(25-50 mg) with statistically signi cant difference.Conclu-sions Low and medium dosage of doxepin(1-25 mg) is effective in improvement of the sleep quality in patients with primary insomnia,but it is necessary to concern the side effects and the effects on sleep structure when treating primary insomnia with medium dosage of doxepin(25 mg).High dosage of doxepin(50 mg) is not recommended to treat primary insomnia.However,this conclusion still needs clinical trials to be further validated.
出处 《中国循证医学杂志》 CSCD 2010年第11期1325-1330,共6页 Chinese Journal of Evidence-based Medicine
基金 兰州大学中央高校基本科研业务费专项资金资助(No.lzujbky-2009-t12) 兰州大学2010教学研究项目(No.201022)
关键词 多虑平 失眠 系统评价 随机对照试验 交叉试验 Doxepin Insomnia Systematic review Randomized controued trial Cross trial
  • 相关文献

参考文献12

  • 1Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Medicine Reviews, 2002, 6(2): 97-111.
  • 2Daley M, Morin CM, LeBlanc M. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep, 2009, 32 (1): 55-64.
  • 3Hajak G, Rodenbeck A, Voderholzer U. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry, 2001, 62(6): 453-463.
  • 4Rodenbeck A, Cohrs S, Jordan W. The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. Psychopharmacology (Berl), 2003, 170(4): 423-428.
  • 5Roth T, Rogowski R, Hull S. Efficacy and safety of doxepin 1 mg, 3 rag, and 6 mg in adults with primary insomnia. Sleep, 2007, 30(11): 1555-1561.
  • 6Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 rag, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry, 2008, 69(10): 1557-1564.
  • 7Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www. cochranehandbook.org.
  • 8Mansbach R. In vitro pharmacological profile of doxepin, a sleep- promoting histamine H1 antagonist. European. Neuropsychopharmacology, 2008, 18(Suppl): 4.
  • 9宿长军,刘煜,李柱一,林宏,李宏增,苗建亭.黛力新与多塞平联合治疗原发性失眠[J].第四军医大学学报,2005,26(21):2010-2012. 被引量:17
  • 10季红宁,赵慧丽,张海燕,鲍丽欣,刘杰.神衰康合用多虑平治疗神经症性失眠临床观察[J].河北医药,2001,23(3):216-217. 被引量:2

二级参考文献13

  • 1刘贤臣,彭秀桂,郭传琴,吴宏新,刘德祥,李传奇.青年学生失眠症状及其相关因素的研究[J].中国临床心理学杂志,1995,3(4):230-232. 被引量:60
  • 2陆亚文,李英霞.失眠症心理咨询与治疗探讨[J].中国神经精神疾病杂志,1996,22(5):287-288. 被引量:14
  • 3吴葆杰.中草药药理学,第3版[M].北京:人民卫生出版社,1992.46-47.
  • 4Walsh JK, Engelhardt CL. Trends in the pharmacologic treatment of insomnia[J]. J Clin Psychiatry, 1992; 52(12, Suppl): 10.
  • 5American Psychiatric Association. Diagnostic and statistical manual of mental disorders[M]. 4th ed. Washington DC: American Psychiatric Association, 1994:186-194.
  • 6Mellinger GD, Balter MB, Unlenhuth EH. Insomnia and its treatment: Prevalence and correlates [J]. Arch Gen Psychiatry, 1985; 42(3):225-232.
  • 7Prisoni GB, De Leo D, Rozzini R, et al. Psychic correlates of sleep symptoms in the elderly [J]. Int J Geriatric Psychiatry, 1992; 7(4): 891-898.
  • 8Charon F, Dramaix M, Mendlewicz J. Epidemiological survey of insomnia subjects in a sample of 1761 outpatients [J]. Neuropsychobiology, 1989;21(3):109-110.
  • 9Deanxit,王莉青.黛安神[J].中国新药杂志,1999,8(2):118-119. 被引量:16
  • 10潘集阳,赵耕原,张晋碚,麦慈任,雷卓然.原发性失眠症患者的焦虑抑郁状态研究[J].中国行为医学科学,2000,9(3):178-179. 被引量:97

共引文献19

同被引文献118

引证文献13

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部